Comparative Effectiveness of Triple Versus Quadruple Therapy in the Treatment of Helicobacter Pylori Induced Gastritis
Key facts
- Who runs it
- Azfar Farogh
- Where
- Pakistan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 752 people enrolled
- Started
- 5 Jan 2024
- Ended
- 30 Dec 2024
- Type of study
- Interventional, 2 groups
- Treatments tested
- Triple Therapy
- Quadruple Therapy
- Record updated
- 31 December 2025
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Adults aged 18-65 years; Confirmed Helicobacter pylori infection based on a positive stool antigen test; Willing and able to provide written informed consent
Who cannot take part
- Prior H. pylori eradication therapy
- History of gastrointestinal bleeding, peptic ulcer perforation, or prior gastric surgery
- Current use of proton pump inhibitors or antibiotics within the previous six weeks
- Use of traditional (Hakeem) medications or herbal remedies affecting gastric function
- History of allergy or hypersensitivity to any of the study drugs (omeprazole, amoxicillin, clarithromycin, metronidazole, tetracycline, or bismuth compounds)
- Chronic renal failure or hepatic dysfunction
- Psychiatric illness or inability to comply with treatment and follow-up
- Pregnancy or lactation
- -
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This randomized controlled trial is designed to compare the efficacy of standard triple therapy versus bismuth-based quadruple therapy for the eradication of Helicobacter pylori-induced gastritis. The study is being conducted at Shahida Islam Medical College, Lodhran, Pakistan. Adult patients with confirmed H. pylori infection are randomly allocated to receive either a 14-day triple therapy regimen or a 14-day bismuth-based quadruple therapy regimen. Eradication of H. pylori is assessed six weeks after completion of treatment using stool antigen testing. The primary outcome measure is the proportion of patients achieving successful eradication of H. pylori.
The 2 groups in the trial
- Triple Therapy GroupTreatment being tested
Participants received Omeprazole 40 mg twice daily, Amoxicillin 1 g twice daily, and Clarithromycin 500 mg twice daily for 14 days.
Treatment: Triple Therapy
- Quadruple Therapy GroupTreatment being tested
Participants received Omeprazole 40 mg twice daily, Metronidazole 400 mg three times daily, Tetracycline 500 mg every six hours, and Bismuth subsalicylate for 14 days.
Treatment: Quadruple Therapy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Comparative Effectiveness of Triple Versus Quadruple Therapy in the Treatment of Helicobacter Pylori Induced Gastritis: A Randomized Controlled Trial
- Record updated
- 31 December 2025